Episona Inc.'s Male Fertility Panel of genomic DNA methylation markers is being developed to detect epigenetic abnormalities in sperm that can indicate severely reduced fertility. The company expects the panel will help urologists steer some patients away from in vitro fertilization and toward other options such as a sperm donor or adoption.

According to co-founder, President and CEO Alan Horsager, the molecular causes of male infertility are poorly understood and current methods to diagnose suspected cases of infertility rely on crude measurements such as sperm count and motility.